Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Adam Sharp

Has grant

Team Leader

Institute of Cancer Research

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom

Recent Grants

Grant: Open

Dissecting the apoptotic and non-apoptotic roles of MCL1 in lethal prostate cancer to deliver innovative treatments to transform patient care

Open Date: 2026-10-01

Close Date: 2028-09-01

Grant: Open

Doctoral Programme in Cancer Research for Healthcare Professionals

Open Date: 2026-10-01

Close Date: 2031-09-01

Grant: Open

AI-driven Omics-Mapping of Key Factors for Long-term Remission in mPCa and Development of Novel Adoptive Cell Immunotherapy.

Open Date: 2025-10-01

Close Date: 2027-09-01

Grant: Open

BAK-Loss Lethal Prostate Cancer: Uncovering Therapeutic Vulnerabilities to Deliver New Treatments and Improve Clinical Outcomes

Open Date: 2025-08-01

Close Date: 2029-07-31

Grant: Open

Developing novel and transformative therapeutic strategies targeting mRNA translation for the treatment of molecularly defined prostate cancer subtypes.

Open Date: 2024-12-01

Close Date: 2027-01-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (21)

Gwenaelle Gravis

Praticien Hospitalier Spécialiste Oncologie; Head of the onco-urology (since 2001) , Head of the outpatient unit (2002-2018) , Reviewer for the Clinical Research protocol (since 2017)

Institut Paoli-Calmettes

FRANCE

Adam Sharp

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies

Molecular landscape of prostate cancers with clival metastases

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer

A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).

Differential coregulator usage mediates Androgen Receptor Splice Variant 7 activity in castration resistant prostate cancer

The 5G (Next Generation AGile Genomically Guided Glioma) Platform Trial - A First-in-world Adaptive Clinical Trial for Precision Treatment of Brain Tumours

Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging

Novel Therapeutic Strategies for Metastatic Prostate Cancer Care

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress

Treatment-related adverse events of antibody drug-conjugates in clinical trials

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.

PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.

Collaborators (21)

Gwenaelle Gravis

Alec Paschalis

Udai Banerji

Ines Figueiredo

Christina Yap

Justin Hwang

Adam Sowalsky

Ignacio Matos

Emma Hall

Michael Haffner

Johann S de Bono

Pasquale Rescigno

Seiji Arai

Cristina Boixareu Fiol

Fay Cafferty

Kristoffer Rohrberg

Ana Aparicio

Crescens Diane Tiu

Edwin Posadas

María de los Dolores Fenor de la Maza

Timothy Yap

Make your next move.